What Are Real Stem Cells — and Where Do They Come From?
The term “stem cell therapy” has become one of the most misused phrases in modern medicine. Clinics across the United States market injections of umbilical cord tissue, Wharton’s jelly, amniotic fluid, and placental extracts as “stem cell treatments” for joint pain, arthritis, and musculoskeletal injuries. Patients pay between $3,000 and $15,000 for these injections. Most of them receive no living stem cells at all.
This is not a gray area. It is a distinction the FDA has been making clearly since at least 2019, and one it is now actively enforcing through warning letters, facility inspections, and federal prosecution.
So what is a real stem cell? A stem cell is a living, undifferentiated cell capable of self-renewal and differentiation into specialized cell types. For orthopedic applications, the relevant population is mesenchymal stem cells (MSCs) — cells that can differentiate into bone, cartilage, tendon, and fat tissue, and that exert powerful anti-inflammatory and signaling effects in injured tissue. These cells exist in meaningful concentrations in two places your physician can access from your own body: your bone marrow and your adipose (fat) tissue.
This is what the FDA calls autologous cellular therapy. Autologous means the cells come from you, are processed minimally, and are returned to you in the same operative session. No shipping. No storage. No donor. No approval required, because you are both the donor and the recipient.
What “Stem Cell Products” Actually Are
Wharton’s jelly, umbilical cord blood, amniotic fluid, and placental tissue are harvested from birth tissue donated by consenting mothers after delivery. They are processed, lyophilized (freeze-dried), bottled, and distributed commercially to clinics under brand names like ReBellaWJ, ReBellaXO, or dozens of similar products. These products are marketed as containing MSCs, exosomes, growth factors, cytokines, and other biologics with regenerative potential.
There are two fundamental problems with this.
First: the cells are not alive. Processing and freeze-drying destroys cell viability. Independent analyses of commercial Wharton’s jelly and amniotic products have consistently found no viable mesenchymal stem cells. What remains is a protein-rich solution of growth factors and extracellular matrix components — biologically active in some respects, but not a stem cell therapy by any definition.
Second: under FDA regulations, these products are not autologous. They come from a different person’s tissue. They have been more than minimally manipulated. They are intended for use that the FDA has ruled does not constitute homologous use under 21 CFR 1271.10(a). This means they require an approved Biologics License Application (BLA) before they can be legally sold or administered. Not one of these commercial products has an approved BLA.
The FDA’s August 2026 Warning to R3 Medical Companies
In August 2026, the FDA’s Center for Biologics Evaluation and Research (CBER) issued a formal warning letter to R3 Medical Companies — a network operating under CEO David L. Greene, MD, that includes Bello Bio LLC, Regen Suppliers LLC, R3 Stem Cell LLC, and R3 Anti-Aging clinics in Scottsdale, Nashville, and Beverly Hills.
The FDA documented that Bello Bio contract-manufactured umbilical cord-derived products — ReBellaWJ, ReBellaXO, and ReBellaXOL — for distribution by Regen Suppliers, alongside an umbilical cord blood product called ReBellaCB. The agency concluded that all four products are unapproved new drugs in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act, and unlicensed biological products in violation of section 351(a)(1) of the Public Health Service Act.
The FDA’s specific findings included: failure to validate aseptic manufacturing processes; sterility testing performed on frozen samples, which can mask contamination; no stability data supporting the 24-month expiration dates assigned to these products; and no written quality control procedures. The company had received a prior FDA warning in 2019 and continued marketing the same products for the same conditions regardless.
R3 Medical Companies was marketing these products aggressively on YouTube, TikTok, Instagram, and Facebook under the handle @R3StemCell. In one video, an employee held vials of ReBellaCB and ReBellaXO up to a patient and stated that these were the patient’s own stem cells with 30 million cells in each vial. They were not the patient’s cells. They were commercial umbilical cord products with no approved indication, manufactured without validated sterility controls, by a company that had already been warned by the FDA seven years earlier. The full warning letter is publicly available at fda.gov (MARCS-CMS 726330, August 14, 2026).
This is not an isolated case. It is the most recent action in a sustained FDA enforcement campaign that has previously targeted Liveyon, Genetech Inc., US Stem Cell Inc., California Stem Cell Treatment Center, and others.
What the Research Shows About Autologous Cellular Therapy
The clinical evidence for autologous cellular therapy in orthopedics is substantive, peer-reviewed, and growing. This is the treatment category that has earned scientific scrutiny — because it involves real, living cells drawn from the patient’s own body and delivered under controlled conditions.
Bone marrow aspirate concentrate (BMAC) and adipose-derived stromal cells (ADSCs) are the two autologous sources with the most clinical data for musculoskeletal indications. Based on articles retrieved from PubMed:
A 2023 prospective comparative clinical trial published in the Journal of Orthopaedic Surgery and Research followed 102 patients with knee osteoarthritis receiving either intra-articular BMAC or ADSC injections. Both groups showed statistically significant improvements in KOOS scores, Oxford Knee Score, and VAS pain scores at six months (p < 0.0001), with patients with moderate osteoarthritis showing the strongest outcomes. (Pintore et al., 2023. DOI: 10.1186/s13018-023-03841-2)
A 2025 exploratory pilot study in the Indian Journal of Orthopaedics compared BMAC and ADSC injections in 60 knee OA patients, quantifying MSC cellularity via CD34+ cell counts. Both groups demonstrated significant improvements in VAS, WOMAC, and range of motion at six months. Bone marrow samples yielded higher MSC counts, with 30 of 32 successful MSC cultures derived from bone marrow aspirates. (Vitali et al., 2025. DOI: 10.1007/s43465-025-01525-z)
A network meta-analysis of 79 randomized controlled trials covering 8,761 knee OA patients, published in The Knee, evaluated the full spectrum of intra-articular injectables. At 12-month follow-up, stromal vascular fraction — an autologous adipose-derived cellular preparation — ranked highest for both pain and functional outcomes across all treatment groups. (Anil et al., 2021. DOI: 10.1016/j.knee.2021.08.008)
A 2022 review in Bone Reports synthesized clinical evidence for bone marrow-derived MSCs in osteoarthritis, osteochondral defects, and avascular necrosis, finding consistent improvements in pain and function and supporting the use of autologous BM-MSCs as a safe and effective treatment for painful knee osteoarthritis. (Pasculli et al., 2022. DOI: 10.1016/j.bonr.2022.101630)
None of this evidence was generated using commercial Wharton’s jelly or umbilical cord products. It was generated using autologous cells drawn from the patient being treated.
Why This Matters: The Patient Is Being Deceived
The patients receiving commercial allogeneic injections are not making uninformed decisions. They are making decisions based on false information. A clinic telling a patient these are your stem cells while injecting a lyophilized commercial product is not offering a different treatment philosophy — it is making a factually false statement to a person in pain who has already exhausted other options.
The downstream harm is real. Patients who spend $8,000 on a commercial allogeneic product and experience no meaningful benefit may conclude that cellular therapy does not work — and never pursue the autologous option that has actual clinical evidence behind it. They may also have received an unapproved biologic manufactured without validated sterility controls.
There is also a safety concern that remains undercharacterized. Allogeneic biologics administered outside of approved clinical trials are not systematically tracked for adverse reactions. The long-term immune response to repeatedly administered commercial cord-derived products in orthopedic patients is not known.
What to Look for in a Cellular Orthobiologics Physician
If you are evaluating cellular therapy for a musculoskeletal condition, the physician doing the evaluation matters more than any product or brand name. Here is what distinguishes someone equipped to actually help you.
Board certification in a relevant specialty. Your physician should hold board certification in sports medicine, physical medicine and rehabilitation, or orthopedic surgery. Diplomate certification in regenerative medicine through the American Board of Regenerative Medicine (DABRM) indicates additional specialty training and examination in this specific field.
Musculoskeletal ultrasound expertise — not just access. Image-guided injection with real-time MSK ultrasound is the standard of care for precision orthobiologic delivery. A physician who performs landmark-guided cellular injections is guessing at placement. The relevant questions are how long the physician has used MSK ultrasound clinically, what they have been trained in, and whether they teach it to other physicians — a meaningful marker of genuine expertise.
A diagnostic evaluation before any treatment recommendation. Candidacy for cellular therapy cannot be determined without examining the affected tissue. If a physician recommends a stem cell procedure before performing a diagnostic ultrasound of the target structure, they have not established what they are treating or whether the proposed treatment is appropriate. This step is non-negotiable.
Transparency about what is being used and why. A qualified physician can explain whether they use BMAC, adipose-derived SVF, PRP, or a combination; how it is processed; what the evidence supports for your specific condition; and why this approach was selected for you. If a clinic cannot explain what is in the product being injected, that is a disqualifying answer.
Honesty about who is not a candidate. Advanced bone-on-bone arthritis with significant joint space loss, complete retracted tendon rupture, and several other presentations do not respond to cellular therapy. The correct recommendation in those cases is a referral to a surgeon. A physician who tells every patient they are a candidate is not evaluating them.
A research and teaching presence. Physicians who publish, teach, and present their methods and outcomes to peers have their work subject to external review. In a specialty where clinical standards are still being established, this accountability structure matters.
The Bottom Line
Real stem cell therapy for orthopedic conditions is autologous. The cells come from your body, are minimally processed, and are returned to you in the same visit by a physician with the training to identify whether you are a candidate, target the tissue precisely, and interpret the result over time.
Commercial Wharton’s jelly, umbilical cord, and amniotic products are not stem cell therapies. They are not regulated as such by the FDA. They do not contain viable stem cells. The companies selling them as stem cell treatments are doing so in violation of federal law — as the FDA’s August 2026 warning to R3 Medical Companies makes unambiguously clear.
If you are considering cellular therapy for a musculoskeletal condition, the first question to ask is not what product is being used. The first question is whether the physician evaluating you has the training, the diagnostic tools, and the intellectual honesty to tell you what your joint actually needs — and whether it is something they can provide.